Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

Related posts

Abia validates climate policy, prioritises disability inclusion – EnviroNews

February 1, 2026

Credibility of France’s climate leadership on the line as Senate votes to revive oil and gas extraction overseas – EnviroNews

January 31, 2026

Source link